Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 10:8:115.
doi: 10.1186/1479-5876-8-115.

High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study

Michele Guida  1 , Antonio Cramarossa, Ettore Fistola, Mariangela Porcelli, Giuseppe Giudice, Katia Lubello, Giuseppe Colucci
Affiliations

High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study

Michele Guida et al. J Transl Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Complete response in patient with mediastinal lymphopaty and bowel metastases treated in Cohort A (schedule d1,8-28).
Figure 2
Figure 2
Dramatic partial response in patient with liver, lymph nodes and subcutaneous metastases treated in Cohort B (schedule d1-21).
Figure 3
Figure 3
Pathological features of a subcutaneous lesion biopsied after 3 cycles of therapy showing a diffuse regression of the neoplastic cells with abundant melanocitic pigment.
Figure 4
Figure 4
Immunohistochemistry staining showed a strong positivity of the neoplastic component for S100 protein, HMB 45 and MART 1. Moreover, an impressive lymphocytic (CD3+, CD4+, CD8+) and macrophage cells (CD68+) infiltration was present.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. doi: 10.3322/canjclin.57.1.43. - DOI - PubMed
    1. Balch CM, Gershenwald JE, Soong SJ. et al.Final Version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206. doi: 10.1200/JCO.2009.23.4799. - DOI - PMC - PubMed
    1. Guida M, Latorre A, Mastria A. et al.Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. Eur J Cancer. 1996;32(4):730–733. doi: 10.1016/0959-8049(95)00662-1. - DOI - PubMed
    1. Chapman PB, Einhorn LH, Meyers ML. et al.Phase III multicenter randomozed trial of the Darmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–2761. - PubMed
    1. Ridolfi R, Sileni VC, Guida M. et al.Cisplatin, Dacarbazine with or without Subcutaneous Interleukin-2 and Alfa Interferon Phase III Randomized Trial: Results of an Italian Multicentric Study in Advanced Melanoma Out-Patients. J Clin Oncol. 2002;20(6):1600–07. doi: 10.1200/JCO.20.6.1600. - DOI - PubMed

MeSH terms